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Abstract
Aggregatibacter actinomycetemcomitans is an oral and systemic pathogen associated with
aggressive forms of periodontitis and with endocarditis. Outer membrane vesicles (OMVs)
released by this species have been demonstrated to deliver effector proteins such as cyto-
lethal distending toxin (CDT) and leukotoxin (LtxA) into human host cells and to act as trig-
gers of innate immunity upon carriage of NOD1- and NOD2-active pathogen-associated
molecular patterns (PAMPs). To improve our understanding of the pathogenicity-associated
functions that A. actinomycetemcomitans exports via OMVs, we studied the proteome of
density gradient-purified OMVs from a rough-colony type clinical isolate, strain 173 (sero-
type e) using liquid chromatography-tandemmass spectrometry (LC-MS/MS). This analysis
yielded the identification of 151 proteins, which were found in at least three out of four inde-
pendent experiments. Data are available via ProteomeXchange with identifier PXD002509.
Through this study, we not only confirmed the vesicle-associated release of LtxA, and the
presence of proteins, which are known to act as immunoreactive antigens in the human
host, but we also identified numerous additional putative virulence-related proteins in the A.
actinomycetemcomitans OMV proteome. The known and putative functions of these pro-
teins include immune evasion, drug targeting, and iron/nutrient acquisition. In summary, our
findings are consistent with an OMV-associated proteome that exhibits several offensive
and defensive functions, and they provide a comprehensive basis to further disclose roles
of A. actinomycetemcomitans OMVs in periodontal and systemic disease.
Introduction
Periodontal diseases are characterized by chronic inflammation of the gingiva, and progressive
destruction of alveolar bone and supporting tissues around the teeth resulting in tooth loss [1].
Colonization by the Gram-negative human pathogen Aggregatibacter actinomycetemcomitans
is strongly associated with aggressive forms of periodontitis in adolescents and young adults
[2, 3], and the organism also is a systemic pathogen, associated with non-oral infections such
as endocarditis [4].
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The prevalence of A. actinomycetemcomitans varies widely with geographic origin, age and
life style of a population [3, 5]. Seven serotypes (a-g) exist, which form genetically divergent lin-
eages [3, 6]. Whole genome sequencing of 14 A. actinomycetemcomitans strains has disclosed a
pangenome of 3301 genes (2034 core and 1267 flexible genes), and it showed that the difference
between any two strains is 0.4–19.5% of the genomic content [7]. The mechanisms by which A.
actinomycetemcomitans causes periodontal attachment loss and systemic disease are not entirely
known. As a highly leukotoxic clone (JP2; serotype b) is strongly linked to disease progression in
North African adolescents [2, 8], leukotoxin (LtxA) may have a major role in aggressive forms of
periodontitis. Like HlyA of Escherichia coli, LtxA is an RTX toxin, which selectively affects human
cells of hematopoetic origin. It binds to the lymphocyte function associated receptor 1 (LFA-1)
and causes disruption of the membrane integrity [9–12]. Moreover, similar to several other
Gram-negative bacteria (e.g. Campylobacter jejuni, Escherichia coli, Salmonella enterica, and Shi-
gella dysenteriae), A. actinomycetemcomitans produces a cytolethal distending toxin (CDT),
which kills host cells including gingival fibroblasts by blocking their proliferation [13–16]. In addi-
tion to LtxA and CDT, accumulating evidence strongly suggests the importance of additional, yet
undisclosed A. actinomycetemcomitans virulence mechanisms in periodontitis [3, 17, 18].
It has been evident for decades that bacteria, archaea, and eukaryotes produce membrane
vesicles (MVs). Membrane vesicles (“Type Zero secretion”) represent a very basic but relevant
mode of protein export by bacteria, and are released by both commensals and pathogens in
vivo and during infection of host cells in vitro [19–23]. Vesicles from both Gram-negative and
Gram-positive bacteria can carry out a number of offensive functions, including targeting con-
centrated virulence factors, and inflammatory stimulants such as LPS and peptidoglycan frag-
ments to host cells and tissues to manipulate the host immune response [24–30]. For
consistency, in this report vesicles liberated by Gram-negative organisms are referred to as
outer membrane vesicles (OMVs). Biogenesis of OMVs is not known in great detail. They are
generated as a result of the budding out of small portions of the outer membrane and the
encapsulation of periplasmic components [31–33]. In chronic localized infections, such as peri-
odontitis OMVs may represent an important source of inflammatory stimulants both locally
and systemically, upon entry into the circulation [34, 35]. For instance, A. actinomycetemcomi-
tansOMVs can deliver biologically active virulence factors (CDT, OmpA) into HeLa cells and
human gingival fibroblasts (HGF) [36]. In addition, the export of LtxA, peptidoglycan-associ-
ated lipoprotein (Pal), and the chaperonin GroEL also involves OMVs [37–40]. We recently
demonstrated that A. actinomycetemcomitans OMVs carrying NOD1- and NOD2-active pepti-
doglycan are internalized into non-phagocytic human cells including gingival fibroblasts [41],
revealing a role of the vesicles as a trigger of innate immunity. Membrane vesicles also exhibit
several defensive functions. For example, it was recently demonstrated that Vibrio cholerae
OMVs contribute to antimicrobial peptide resistance [42], and that biologically active β-lacta-
mase is released via vesicles in Staphylococcus aureus [43]. There is also evidence thatMorax-
ella catarrhalis OMVs mediate immune evasion by inactivating complement factor C3 [44, 45].
Accumulating knowledge from genomic, proteomic and transcriptomic analyses of A. acti-
nomycetemcomitans strains provides novel, comprehensive information on virulence-related
properties of this organism, and represents a good molecular basis for further disclosing its
pathogenicity mechanisms and role in periodontal and systemic disease [7, 18, 46–48]. In
recent years, several high-throughput proteomics studies have revealed the identity of vesicle
proteins in an array of bacterial species [28, 49]. However, the detailed composition of the A.
actinomycetemcomitans OMV proteome was not known. To improve our understanding of the
virulence potential of A. actinomycetemcomitansOMVs, we have used liquid chromatography-
tandem mass spectrometry (LC-MS/MS) to identify the OMV-associated proteome of strain
173 (serotype e). This strain was selected because it was earlier assessed with respect to both
Proteomics of A. actinomycetemcomitansOMVs
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production of LtxA and CDT [17, 50], which provides a basis for the analysis of unknown viru-
lence-related proteins. In this study we identified 151 proteins in the A. actinomycetemcomi-
tansOMV-associated proteome. In addition to confirming their immunoreactive potential,
and leukotoxic activity, we provide a comprehensive overview of additional putative offensive
and defensive mechanisms of the vesicles, which can serve as the groundwork for further dis-
closing their role in periodontal and systemic disease.
Materials and Methods
Bacterial strains and growth conditions
The A. actinomycetemcomitans serotype e strain, 173 (rough colony type) belongs to a strain
collection sampled from an adolescent West African population, and was isolated from an indi-
vidual with tooth attachment loss at baseline [50]. Strain D7SS is a smooth-colony derivative of
D7S (serotype a), which was originally isolated from a patient with aggressive periodontal dis-
ease [51]. Mutant derivatives of D7SS, D7SSΔltxA ΔcdtABC [52], and D7SS-p (pal-deficient)
[53] were constructed earlier. JP2 (serotype b) is a highly leukotoxic strain (serotype b) [54].
The A. actinomycetemcomitans strains were routinely cultivated in air supplemented with 5%
CO2, at 37°C as previously described [39], on blood agar plates (5% defibrinated horse blood, 5
mg hemin/l, 10 mg Vitamin K/l, Columbia agar base).
SDS-PAGE andWestern immunoblotting
The procedures used for SDS-PAGE and immunoblot analysis have been described previously
[53, 55]. Gels were stained using non-ammonical Silver-staining (BioRad). For Western blot
experiments, we used a patient serum from a periodontitis subject, which exhibits strong reac-
tivity to A. actinomycetemcomitans antigens [56] (final dilution 1:2,000). As a control, a serum
sampled from a periodontally healthy, A. actinomycetemcomitans-negative individual was used
(1:2,000). Polyclonal antisera made in rabbit against E. coli GroEL protein (Sigma-Aldrich),
and against whole A. actinomycetemcomitans serotype e bacterial cells [57] were used at
1:8,000 and 1:10,000 final dilutions, respectively. As secondary antibody, anti-human or anti-
rabbit horseradish peroxidase (HRP)-conjugate (Jackson ImmunoResearch, Newmarket, UK)
was used (1:10,000). Immunoreactive bands were visualized using Clarity™Western ECL Sub-
strate (Bio-Rad) and the ChemiDoc™ XRS+ System (Bio-Rad).
Isolation and purification of outer membrane vesicles
OMVs were isolated from A. actinomycetemcomitans cells harvested from an average of ten
blood agar plates, using ultracentrifugation as described earlier [36, 41]. OMV pellets were
washed twice with PBS (85,000 × g; 2 h, 4°C) using a 70 Ti rotor (Beckman Instruments Inc.),
and then used as the OMV preparation. The yield of OMVs was estimated by quantifying vesi-
cle preparations for protein content using a Picodrop™ (Picodrop Ltd.) [41]. To assess the uni-
formity of OMV preparations, samples were validated by atomic force microscopy (AFM), and
SDS-PAGE. OMVs were also checked for absence of bacterial contamination by cultivating
small aliquots on blood agar plates in air supplemented with 5% CO2, at 37°C for 3 days. To
separate the vesicles from free or loosely associated proteins, OMV preparations were purified
using density gradient centrifugation [36, 41]. In this gradient, OMVs migrate to positions
equal to their density. Only proteins integral, internal, or tightly associated with membrane lip-
ids will move significantly through the gradient [58]. For this procedure, OMV pellets were
resuspended in 50 mMHEPES (pH 6.8) and then adjusted to 45% OptiPrep (Sigma-Aldrich)
in a final volume of 150 μl. The sample was transferred to the bottom of a 4-ml ultracentrifuge
Proteomics of A. actinomycetemcomitansOMVs
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tube, and then different OptiPrep-HEPES layers were sequentially added as follows: 900 μl of
35%, 900 μl of 30%, 660 μl of 25%, 660 μl of 20%, 400 μl of 15%, and 500 μl of 10%. Gradients
were centrifuged at 180,000 × g (3 h, 4°C) in an SW 60 Ti rotor (Beckman Instruments Inc.),
and fractions of equal volumes (200 μl) were removed sequentially from the top.
Preparation of OMV Samples for Liquid Chromatography Mass
Spectrometry (LC-MS/MS)
After SDS-PAGE analysis, selected fractions from the Optiprep density gradient were pooled
into a total volume of 780 μl. Subsequently, 400 μl HEPES buffer (50 mM, pH 7.8) was added
to increase the pH to>7. For reduction of disulfide bonds, dithiotreitol (DTT) was added at 50
mM final concentration, and the sample was heated for 20 min at 60°C. For the alkylation reac-
tion, iodacetamide (IAM) was added to the sample at a final concentration of 20 mM. After 60
min treatment in the dark, the OMV proteins were precipitated using trichloroacetic acid
(TCA), and stored in -20°C overnight. The next day, the sample was centrifuged in a Beckman
Coulter Avanti J-20 XP centrifuge (JA 18–1 Beckman Instruments Inc., California, USA) at
16,000 × g for 30 min at 4°C, followed by a subsequent washing step where the sample was cen-
trifuged at 16,000 × g for 15 min with 80% ethanol. Finally, the OMV pellet was dried in air,
and used for the preparation of an in-solution digest for LC-MS/MS analysis.
Preparation of in-solution digests of OMV proteins
A dried pellet of TCA-precipitated OMVs was resuspended in 15 μl fresh 8 M urea and 20 μl of
50 mM ammonium bicarbonate containing 0.2% ProteaseMaxTM surfactant (Promega Biotech,
Nacka, Sweden). The vesicle proteins were dissolved by shaking at 150 rpm for 20 min at 37°C.
After the solubilization, 50 μl of 50 mM ammonium bicarbonate, 10.4 μl of Milli Q water, 1 μl
of 50 mM ammonium bicarbonate containing 1% ProteaseMax surfactant, and 3.6 μl of 0.5 μg/
μl trypsin stock solution (sequencing grade trypsin, Promega Biotech, Nacka, Sweden) were
added. The final concentrations were 40 mM ammonium bicarbonate, 0.05% ProteaseMax sur-
factant, 1.2 M urea and 18 ng/ml of trypsin in a volume of 0.1 ml. To generate peptides for
mass spectrometry the in-solution digestion was performed for either 1 to 1.5 hours at 50°C or
for 2 to 3 hours at 37°C [59]. Finally, the digestion was stopped by addition of 10% trifluoroace-
tic acid to a final concentration of 0.5–1.0%, and the peptides were desalted using homemade
reversed phase micro columns [60, 61]. The bound peptides were eluted using 0.1% formic
acid containing 50% acetonitrile. The solvent was removed using a speedvac and the peptides
were dissolved in 0.1% formic acid for further analysis by mass spectrometry.
LC-MS/MS analysis and data processing
The peptides generated by in-solution digestion were analyzed by LC-MS/MS (DDA, 5 MS/MS
channels) using a Synapt G2 mass spectrometer (Waters, Sollentuna, Sweden) linked to a nano
UPLC (Waters, Sollentuna, Sweden). Separation of the peptides was performed by C18 nano
reversed phase chromatography (Acquity nano UPLC column 1.8 mmHSS T3 75 mm × 200
mm). The peptides were separated at a flow rate of 300 nl/min using a 4 h long linear gradient
(1 to 30 percent acetonitrile for 3 h, followed by 30 to 50 percent acetonitrile for 1 h). Spectra
processing was performed using the ProteinLynx Global Server 2.5.2 software (Waters, Sollen-
tuna, Sweden) using lockspray calibration and fast de-isotoping for the MS and MS/MS mode.
In addition, the spectra were also processed using the Mascot Distiller (version 2.4.3.3, Matrix
Science, London, UK) and the standard settings for DDA data fromWaters instruments. Data-
base searches using the peaklist files of the processed mass spectra were performed using the
Mascot search engine (version 2.4, MatrixScience, London, UK) in the database of A.
Proteomics of A. actinomycetemcomitansOMVs
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actinomycetemcomitans serotype e strain SC1083, which is available at Ensembl Bacteria at:
http://bacteria.ensembl.org/aggregatibacter_actinomycetemcomitans_serotype_e_str_sc1083/
Info/Index. This database was selected because the genome of strain 173 was not available, and
it contained the gene models from a strain of the same serotype. The search parameters permit-
ted mass errors of 20 ppm (MS mode) and 0.1 Da (MS/MS mode), respectively. Modifications
included variable oxidation of methionine, N-terminal acetylation, deamidation (N,Q) and
fixed cysteine derivation by carbamidomethylation. The false discovery rate was<1%. Compi-
lation of non-redundant protein lists was performed using the Protein Extractor of the Protein-
Scape server (version 3, Bruker Daltonik GmbH, Bremen, Germany). Ion scores of individual
MS/MS spectra lower than 30 and Mascot protein scores lower than 100 were not considered
for the compilation of the results. The LC-MS/MS analysis was performed with four indepen-
dent OMV preparations. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium [62] via the PRIDE partner repository with the dataset identi-
fier PXD002509 and 10.6019/PXD002509.
Bioinformatics analysis of the LC-MS/MS results
The final result list was assembled using the proteins that were detected in at least three of the
four OMV preparations that were analyzed. It included 151 proteins that were sorted according
to their Clusters of Orthologous groups (COG) categories. COG groups were created manually
by using the gene identifiers for searches in the COG database at http://www.ncbi.nlm.nih.gov/
Structure/cdd/wrpsb.cgi. The COG classifiers were grouped according to the definitions in the
conserved domains database at National Center for Biotechnology Information (NCBI) [63].
The subcellular locations of the identified proteins were predicted using the program PSORT3b
3.0 [64], and members of KEGG pathways were identified using the KOBAS 2.0 server [65]
and the annotations of the A. actinomycetemcomitans strain D7S genome as a template. The
proteins were also subject to in silico analysis using VirulentPred (http://203.92.44.117/
virulent/submit.html), which predicts bacterial virulence proteins based on their sequences
information [66].
Atomic Force Microscopy
For AFM, samples of OMVs were diluted with ultrapure water (Millipore) and placed onto a
freshly cleaved mica surface. Samples were incubated for 5 min at room temperature, washed
with ultrapure water, and then placed in a desiccator for ~2 h in order to dry. The samples
were finally magnified through a Nanoscope V Atomic Force Microscope (Bruker AXS GmbH,
Karlsruhe, Germany), using tapping mode. Final images were plane fitted in both the x and y
axes and are presented in amplitude mode.
Cell cultures and determination of leukotoxic activity of OMVs
Human myeloid monocytic THP-1 (ATCC 16) cells were cultivated in RPMI 1640 (Sigma-
Aldrich, St Louis, MI, USA) with 10% fetal bovine serum (FBS) (Sigma-Aldrich) at 37°C in 5%
CO2. Leukotoxic activity of A. actinomycetemcomitans OMVs was determined by quantitating
the release of lactate dehydrogenase (LDH) from treated THP-1 cells as described earlier [17,
67]. In brief, aliquots of 100μl (1×106 cells per ml) of phorbol 12-myristate 13 acetate (PMA)-
differentiated THP-1 cells were incubated with OMVs for 120 min such that the final OMV
protein concentration was 100 μg/ml. As control treatment, PBS buffer was used. The release
of LDH was expressed as % of the maximal release (100%) caused by incubation with 0.1% Tri-
ton X-100.
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PLOSONE | DOI:10.1371/journal.pone.0138591 September 18, 2015 5 / 21
Results and Discussion
Purification of OMVs from the A. actinomycetemcomitans serotype e
strain 173
To study outer membrane vesicle release by A. actinomycetemcomitans, vesicles were purified
from strain 173 cells grown on agar (Fig 1A). The seroreactivity of the isolated OMVs was con-
firmed using a rabbit antiserum made against whole A. actinomycetemcomitans serotype e bac-
terial cells (Fig 1B). SDS-PAGE analysis of density gradient fractions of OMVs revealed a
major population of OMVs, peaking approximately in the fractions 8 to 12 (Fig 1C), which is
consistent with our earlier analyses of OMVs obtained from various A. actinomycetemcomitans
Fig 1. Purification of OMVs from A. actinomycetemcomitans strain 173. (A) Atomic force micrograph of OMVs obtained from strain 173 after density
gradient centrifugation. Bar = 300 nm. (B) Reactivity of the isolated strain 173 OMVs (lane 1) to a rabbit antiserummade against whole A.
actinomycetemcomitans serotype e bacterial cells. OMVs from strain D7SS (serotype a) are loaded in lane 2. Samples equal to 10 μg protein were applied
on the gel. (C) SDS-PAGE analysis of density gradient fractions of strain 173 OMVs. Fractions (15 μl loaded on the gel) are numbered according to
increasing density. The central fractions (8–12) were pooled and subject to LC-MS/MS analysis. The sizes (kDa) of the proteins in the pre-stained molecular
weight marker (M) are indicated along the left side of the gels in panel B, and C. The images show one representative experiment.
doi:10.1371/journal.pone.0138591.g001
Proteomics of A. actinomycetemcomitansOMVs
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strains [36]. To identify the proteins of the purified OMVs of strain 173, the central fractions
(8–12) were pooled and used for further analysis by LC-MS/MS. The analysis of the OMV pro-
teome included four independent preparations.
Identification of A. actinomycetemcomitans strain 173 OMV proteins by
LC-MS/MS, and their predicted subcellular distribution
In total, 504 proteins were identified by LC-MS/MS in at least one of the four analyzed inde-
pendent preparations of A. actinomycetemcomitans strain 173 OMVs. Out of these proteins,
151 were present in three of the four preparations analyzed, and defined as the OMV proteome
in the present study (S1 Fig, S1 and S2 Tables). The number of 151 identified proteins is within
the range of proteins detected in several high-throughput analyses of bacterial vesicle prote-
omes [28, 49]. To predict the subcellular localizations of the OMV proteins, PSORT3b 3.0 was
used. According to our findings (Fig 2A), of the 151 proteins of the OMV proteome, two were
predicted to be extracellular, 19 to be located in the outer membrane, 7 to be periplasmic, 23 to
Fig 2. Proportions of predicted subcellular locations of the A. actinomycetemcomitans strain 173
OMV proteins identified by LC-MS/MS using PSORT3b. (A) Predicted subcellular locations of the 151
OMV proteins that were identified in at least three out of four independent vesicle preparations that were
analyzed. (B) Predicted subcellular locations of all 2161 proteins encoded in the genome database of A.
actinomycetemcomitans serotype e strain SC1083 that was used for the database searches of the LC-MS/
MS analyses.
doi:10.1371/journal.pone.0138591.g002
Proteomics of A. actinomycetemcomitansOMVs
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be located in the inner membrane, and 78 to be cytoplasmic. The relative proportions of proteins
with predicted locations in the outer membrane and in the periplasm were found to be substan-
tially higher among the 151 proteins than among the entire set of 2161 proteins encoded in the
A. actinomycetemcomitans serotype e genome that was used for the database searches of the
LC-MS/MS analyses (Fig 2B). This is in accordance with an enrichment of proteins derived from
these subcellular fractions in OMVs. Identification of relatively large numbers of cytoplasmic
proteins in OMVs was also observed in several other recent studies, even though the vesicles
were purified using a density gradient [68–71]. Based on such observations it has been suggested
that some cytoplasmic proteins may in fact be sorted into bacterial membrane vesicles [49, 72]. It
is an area for future research to disclose mechanisms how and why these proteins might be
selected for export via vesicles, and how vesicles incorporate other cytosolic material such as
nucleic acid fragments [73–75]. One plausible mechanism might be the formation of double
bilayered outer-inner membrane vesicles, as was demonstrated for Shewanella vesiculosa [76].
The observation that cytoplasmic proteins are present in OMV proteomes may also be due to
that some of these proteins exhibit moonlighting capacities [77]. Moonlighting proteins comprise
a subclass of multifunctional proteins in which more than one biochemical or biophysical func-
tion is contained within one polypeptide chain [78]. Moreover, presence of cytoplasmic proteins
in OMV proteomes may be a result of cell lysis. However, among the proteins identified by
LC-MS/MS (S1 and S2 Tables) we did not detect the cyclic nucleotide-binding domain protein
(also known as cyclic AMP receptor protein [CRP]; GI:347994078), which is frequently used as a
lysis marker in our studies for assessing the release of proteins by A. actinomycetemcomitans
strains [18, 39, 79]. Notably, CRP was not detected in the extracellular medium of A. actinomyce-
temcomitans strain D7S cultivated as biofilm for up to 3 days, but could be released upon deliber-
ate lysis of the bacterial cells [39, 79]. Therefore, absence of CRP in our present OMV
preparations would argue against protein release due to bacterial lysis.
Functional classification of proteins identified in A.
actinomycetemcomitans strain 173 OMVs
To determine putative functions of the 151 proteins in the strain 173 OMV proteome, they were
sorted according to their Cluster of Orthologous Groups (COG) definitions (Fig 3A). The group of
151 vesicle proteins had 182 of the 2274 COG definitions present in the database of the gene mod-
els of A. actinomycetemcomitans serotype e strain SC1083 (Fig 3B, S4 Table). The four largest COG
groups recognized in the OMV proteome were found to be translation, ribosomal structure and
biogenesis (22 of 237 COG definitions), carbohydrate transport and metabolism (21 of 186), post-
translational modification, protein turnover, and chaperone activity (21 of 153), and cell wall,
membrane, and envelope biogenesis (19 of 153). The relative abundance ratios of these COG
groups were clearly higher in the OMV proteome than in the entire genome ofA. actinomycetem-
comitans serotype e strain SC1083. In particular, the group of post-translational modification,
protein turnover, and chaperones stood out, accounting for 11.5% of the COG definitions in the
experimental OMV proteome as compared to 5.5% of the entire genome. Taken together, these
findings indicate that the OMV proteome may exhibit specific functions. This result is similar to
COG categorization of the OMV proteomic content in a number of other species, e.g. C. jejuni, and
Edwardsiella tarda [80, 81], and of cell envelope fractions of A. actinomycetemcomitans cells [82].
Virulence-related mechanisms of A. actinomycetemcomitans vesicles
as suggested by proteins identified in the strain 173 OMV proteome
To gain insight into the virulence potential of the strain 173 OMV proteome, and to obtain an
overview of putative functional roles of the vesicles, the 151 proteins of the proteome identified
Proteomics of A. actinomycetemcomitansOMVs
PLOSONE | DOI:10.1371/journal.pone.0138591 September 18, 2015 8 / 21
by LC-MS/MS were manually searched for their earlier reported involvement in A. actinomyce-
temcomitans offense and defense, and in other bacteria. As summarized below, this screening
revealed 49 proteins of particular interest (Table 1). As a complement to the literature search,
the 151 vesicle proteins were also subject to in silico analysis using VirulentPred, an algorithm
Fig 3. Functional classification of A. actinomycetemcomitans strain 173 OMV proteins. The 151 OMV proteins that were identified by LC-MS/MS in
three out of four of the vesicle preparations were sorted according their COG groups as indicated. (A) This figure shows the proportions of the major groups of
COG domains that were found in the OMV proteins, which were identified in this study. In total 182 COG domains were found in the 151 proteins. (B) This
figure shows the corresponding COG domains that are present in the entire set of gene models of the genome of A. actinomycetemcomitans serotype e
strain SC1083. The 2161 gene models of this strain contained 2274 COG domains.
doi:10.1371/journal.pone.0138591.g003
Proteomics of A. actinomycetemcomitansOMVs
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developed to predict putative novel virulence factors (S3 Table). Using this approach 60 of the
OMV proteins (40%) were predicted to be associated with virulence, including most of the
proteins revealed in the initial literature search. Our findings suggest that A. actinomycetemco-
mitans OMVs may exhibit several offensive and defensive functions analogous to those
described in recent reviews, including immune evasion, drug targeting, and iron/nutrient
acquisition [28–30].
Immunoreactivity and proinflammatory activity
According to our data, the strain 173 OMV proteome contains several proteins earlier demon-
strated to act as immunoreactive antigens in the human host. LtxA, Omp39, RcpA (referred to
as GspD in the database used; GI:347992426), RcpC (FlpC; GI:347992425), TadA, TadD, TadZ
(FlpD; GI:347992428), and YaeT (also known as BamA) were recognized exclusively by anti-
bodies in sera from subjects with a proven A. actinomycetemcomitans infection [47]. Moreover,
the OmpA-like protein (GI:347991272; also referred to as Omp29 or Omp34), which is a major
protein component of A. actinomycetemcomitans OMVs [40], is immunoreactive in patients
with periodontitis, and so are Omp18/16, Omp100 (GI:347992912; also referred to ApiA) [53,
83–85]. The ability of Pal to elicit proinflammatory responses in human cells has been demon-
strated [39, 79]. There is also evidence that Omp100 induces the expression of proinflamma-
tory cytokines in vitro [86]. Finally, GroEL is implicated as an immunodominant A.
actinomycetemcomitans antigen, which promotes epithelial cell proliferation [38, 87–89]. Car-
riage of GroEL by OMVs also suggests the possibility that vesicles may contribute to alveolar
bone resorption [87, 90]. Western blot analysis was used to corroborate our LC-MS/MS find-
ings. In contrast to a control serum from an A. actinomycetemcomitans-negative subject, which
mainly produced faint signals, an A. actinomycetemcomitans-responsive patient serum strongly
reacted to a number of proteins in strain 173 OMV preparations, including LtxA and Pal (Fig
4A). The observation that Pal is a major immunoreactive antigen of the vesicles is in line with
patterns of patient serum reactivity to A. actinomycetemcomitans outer membrane protein
preparations [53]. Likewise, the relatively strong reactivity of the control serum to Pal (Fig 4A)
is consistent with presence of cross-reacting antibodies to Pal produced by other oral and/or
non-oral Gram-negative species [53]. We deduced that the60 kDa immunoreactive band
Table 1. Virulence-related mechanisms of A. actinomycetemcomitans vesicles as suggested by proteins identified in the strain 173 OMV prote-
ome. The 151 proteins of the strain 173 OMV proteome identified by LC-MS/MS were manually searched for their earlier reported involvement in A. actino-
mycetemcomitans offense and defense, and in other bacteria. The listed proteins are discussed in the main text.
Type of OMV function Shown for A. actinomycetemcomitans proteina) Shown for paralogue in other bacteria, or predicted based
on protein amino acid sequence
Immunoreactivity and/or
proinﬂammatory activity
GroEL, LtxA, OmpA-like protein, Omp18/16, Omp39,
Omp100, Pal, RcpA, RcpC, TadA, TadD, TadZ, YaeT
OmpA
Cytotoxicity LtxA, GroEL OmpA-like protein, OmpA
Adhesion/invasion Omp100, RcpA, RcpB, RcpC, TadA, TadD, TadE,
TadF, TadG, TadZ
Immune evasion BilR1, Omp100 Factor H-binding protein, OmpA-like protein, OmpA
Drug targeting TdeA AcrA, DNA gyrase, elongation factor G, organic solvent
tolerance protein, penicillin-binding protein 1A, ribosomal
proteins (n = 16), RNA polymerase, TolB
Scavenging of iron and
nutrients
Ferric transporter ATP-binding subunit, Ferritin-like protein,
Omp64, putrescine/spermidine ABC transporter ATPase
protein, TonB-dependent siderophore receptor
a) Full protein descriptions as appearing in the genome database used, and their accession numbers are listed in S1, S2, and S3 Tables.
doi:10.1371/journal.pone.0138591.t001
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(Fig 4A) might correspond to GroEL, as this protein was detected in the OMVs using a GroEL-
specific rabbit antiserum (Fig 4B). A membrane vesicle preparation from Staphylococcus aureus
strain 8325–4 [91] was here loaded as a negative control for GroEL, as this protein, which
appears to be essential for bacterial growth [92], was not identified in S. aureusmembrane vesi-
cle proteomes [93, 94]. In summary, our observations support the notion that the A. actinomy-
cetemcomitansOMV proteome represents a potent source of multiple proinflammatory
stimulants. Our data also suggest a potential role of A. actinomycetemcomitans OMVs as
immunogens for vaccines against periodontal disease, in a similar manner as vesicles from Por-
phyromonas gingivalis, which carry several proteins exhibiting strong immunogenicity in a
mouse vaccine model [95, 96].
Fig 4. Immunoreactivity of A. actinomycetemcomitansOMVs. (A) Western blot analysis of reactivity of
human sera with OMVs obtained from the A. actinomycetemcomitans strains 173 (lanes 1 and 5), D7SS
(lanes 2 and 6), D7SS-p (Δpal; lanes 3 and 7), and D7SS ΔltxA ΔcdtABC (lanes 4 and 8). An A.
actinomycetemcomitans-responsive serum from a periodontitis subject (a) and from a periodontally healthy,
A. actinomycetemcomitans-negative individual (b) was used for the immunodetection, respectively. (B)
Western blot detection using a polyclonal antiserum specific for E. coliGroEL. Vesicles obtained from A.
actinomycetemcomitans strains 173 (lane 1), and D7SS (lane 2), and from S. aureus strain 8325–4 [91] (lane
3) were analyzed. Samples equal to 10 μg protein were applied on the gels. Reactive bands corresponding to
LtxA, Pal, and GroEL are indicated with arrowheads. The sizes (kDa) of the proteins in the pre-stained
molecular weight marker (M) are indicated along the left side.
doi:10.1371/journal.pone.0138591.g004
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Cytotoxicity: Leukotoxic activity
LtxA was identified in OMVs from the serotype e strain 173, which is consistent with earlier
reports assessing vesicles derived from serotype a, and b strains [36, 40]. To confirm the pres-
ence of biologically active LtxA in the strain 173 OMVs, lysis of THP-1 cells incubated with
vesicles was quantitated using an LDH release assay (Materials and Methods). This revealed
that OMVs from strain 173 exhibited leukotoxic activity, albeit at a level approximately four
times lower than vesicles from the highly leukotoxic strain JP2 (Fig 5). This relative difference
in leukotoxicity is consistent with observations assessing extracts from these two A. actinomy-
cetemcomitans strains [17]. The leukotoxicity of strain 173 OMVs was similar to that of vesicles
from D7SS, which is considered a minimally leukotoxic strain [97]. Among the identified vesi-
cle proteins, also GroEL may contribute to OMV cytotoxicity as judged by the deleterious effect
of this protein on human epithelial cells [38]. It is not known if the OmpA-like protein
Omp29/Omp34, or its paralogue OmpA (GI:347992918) may play a role in OMV cytotoxicity
towards human cells as has been demonstrated with the nosocomial pathogen Acinetobacter
baumanii [98]. We note that CDT was not identified in the strain 173 OMV proteome, whereas
this toxin is evidently released in association with vesicles by a number of other A. actinomyce-
temcomitans strains of serotypes a, b, and c [36]. This is consistent with observations that strain
173 lacks cytolethal distending activity, which appears to be due to an incomplete subset of the
cdt-encoding genes [50].
Adhesion and invasion
A number of proteins that may contribute to adherence of vesicles to host cells were identified
in the strain 173 OMV proteome. Omp100 promotes adhesion of A. actinomycetemcomitans
cells, and their invasion of human gingival keratinocytes [86, 99]. Moreover, RcpA, RcpB,
RcpC, RadZ, TadA, TadD, TadE, TadF, and TadG are components of the A. actinomycetemco-
mitans tad (tight adherence) gene locus, which mediates adhesion, and is required for virulence
in a rat model for periodontal disease [100]. Recent evidence has supported the internalization
of A. actinomycetemcomitans OMVs into non-phagocytic human cells such as gingival fibro-
blasts [41]. However, it is not known whether specific OMV-associated adhesins would be
Fig 5. Leukotoxic activity of OMVs obtained from the indicated A. actinomycetemcomitans strains.
THP-1 cells were incubated with OMVs (final concentration: 100 μg/ml) for 120 min. Release of LDH was
determined as described in Materials and Methods, and is expressed as % of the maximal release (100%)
caused by incubation with 0.1% Triton X-100. The results shown are means + standard error of the means
(SEM) from three independent experiments.
doi:10.1371/journal.pone.0138591.g005
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involved in adherence of the vesicles to host cells, comparable to the roles of Helicobacter pylori
BabA, SabA, and VacA,M. catarrhalis UspA1, and Pseudomonas aeruginosa aminopeptidase
[28, 29].
Immune evasion
A subset of proteins that may play a role in immune suppression and evasion were identified in
the strain 173 OMV proteome. A hypothetical protein (GI: 347993884) exhibits86% amino
acid identity to BilR1, which is a recently recognized A. actinomycetemcomitans IL-1β-binding
lipoprotein [101]. Carriage of such receptor by OMVs suggests that they might enhance bacte-
rial immune evasion by sequestering IL-1β to reduce inflammation. A. actinomycetemcomitans
strains are typically resistant to killing by human serum [86], and our present results suggest
the possibility that OMVs may play a role in serum survival. For example, Omp100 was dem-
onstrated to be important for serum resistance of A. actinomycetemcomitans strain IDH781
(serotype d), which appeared to be a result of Omp100-mediated binding of Factor H to the
bacterial surface [86]. Moreover, we identified factor H-binding protein, a paralogue to the
protein of Neisseria spp. that is critical for survival of meningococci in the human host [102].
Whether the A. actinomycetemcomitans factor-H binding protein might play a similar func-
tional role is not known. Also OmpA might interact with human serum factors to contribute to
serum resistance, analogously to findings obtained using A. baumannii, and E. coli bacterial
cells [103, 104].
Drug targeting
The strain 173 OMV proteome was found to contain proteins that could bind to/serve as tar-
gets for drugs. There are antibiotics that directly target DNA gyrase [105], elongation factor G
[106], organic solvent resistance protein (also known as LptD or Imp/OstA) [107], penicillin-
binding protein 1A [108], and RNA polymerase [109]. Also, TolB is a potential drug target
[110]. Identification of ribosomal proteins in the OMV proteome is in accordance with detec-
tion of rRNA fragments in OMVs from other organisms [74]. Our findings are also consistent
with other proteomics studies on vesicles from various bacterial species, e.g. S. aureus and P.
aeruginosa [93, 94, 111]. For example ribosomal protein S12 was identified in such studies,
which is bound by several antibiotics including aminoglycosides [111, 112]. Whether presence
of such drug target proteins in vesicles would play a functional role during infection is not
known. However, intriguingly, it was shown that the aminoglycoside gentamicin bound to the
surface of tentative OMVs of P. aeruginosa [113]. Hence, vesicles may have the ability to bind
directly with some antibiotics, thereby lowering their local free concentrations, contributing to
protection of the bacterial cell. Efflux systems, analogously might function as binding proteins
for their substrates in OMVs. Among such proteins in the OMV proteome, TdeA is a TolC-
like protein that is required for secretion of LtxA, and resistance to antimicrobial compounds.
As judged by homology, this protein may represent a component of a drug efflux porin system
in A. actinomycetemcomitans [114]. Similarly, AcrA is a component of the tripartite AcrAB--
TolC multidrug efflux pump, which is well characterized in E. coli [115, 116].
Scavenging of iron and nutrients
Ferritin-like protein, ferric transporter ATP-binding subunit, putrescine/spermidine ABC
transporter ATPase protein, a TonB-dependent siderophore receptor, and Omp64, which has a
TonB-like iron-binding site in the C-terminus [83] were also identified in the strain 173 OMV
proteome. This suggests that the vesicles could play a role in scavenging iron and nutrients,
which might be subsequently released in the vicinity of and provided to bacterial cells. This is
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consistent with a number of previous proteomics studies of OMVs, identifying vesicle-associ-
ated TonB-dependent receptors, metal ion binding proteins, ABC transporters, and machiner-
ies for ATP synthesis, supporting the idea that OMVs may collect and concentrate scarce ions
and nutrients for the consumption of bacterial cells [28, 49, 71, 117, 118]. Interestingly, such a
role of OMVs, also allowing intraspecies nutrient transfer was recently demonstrated regarding
carbon flux between several species of bacteria and cyanobacteria [119].
Conclusions
In conclusion, we have characterized the OMV-associated proteome of the rough A. actinomy-
cetemcomitans serotype e strain, 173 by LC-MS/MS, and used manual literature search and the
VirulentPred algorithm to assess the virulence potential of this subproteome. To the best of
our knowledge, this work represents the first proteomic study of purified A. actinomycetemco-
mitans OMVs. Apparently, the virulence potential may be subject to variation among A. acti-
nomycetemcomitans strains, including their released OMVs. As an example, CDT was not
identified in the strain 173 OMV proteome, whereas this toxin is evidently released in associa-
tion with vesicles by a number of other A. actinomycetemcomitans strains. Nevertheless, our
results suggest that a reasonably large part of the OMV proteins may contribute to the viru-
lence potential of the vesicles. Such proteins include established virulence factors like LtxA,
and major antigens such as Pal, which is also suggesting a potential role of A. actinomycetemco-
mitans OMVs as immunogens for future vaccines against periodontal disease. Moreover, by
identifying numerous additional putative virulence-related proteins in the vesicle proteome,
our work lays the molecular groundwork for novel mechanistical studies that for instance
could elucidate the roles of A. actinomycetemcomitansOMVs in immune evasion, drug target-
ing, and iron/nutrient acquisition. Finally, as compared to several recent high-throughput pro-
teomics studies on OMVs, we identified relatively large numbers of cytoplasmic proteins in the
vesicles, and we conclude that it is an area of interest for future research to disclose mecha-
nisms how such proteins might be targeted for vesicle export.
Supporting Information
S1 Fig. Venn diagram obtained from the comparison of the LC-MS/MS-identified proteins
of the four independent A. actinomycetemcomitans strain 173 OMV preparations. In total
504 proteins were identified, out of which 151 were present in at least three out of the four
preparations that were analyzed.
(TIF)
S1 Table. Proteins identified by LC-MS/MS in at least one of the four independent OMV
preparations of A. actinomycetemcomitans strain 173. In total, 504 proteins were identified.
(XLSX)
S2 Table. Proteins identified by LC-MS/MS in at least three out of four independent OMV
preparations of A. actinomycetemcomitans strain 173. A total of 151 proteins were identified.
(XLSX)
S3 Table. VirulentPred screening of the 151 proteins in the A. actinomycetemcomitans
strain 173 OMV proteome.Where available, references are included that support virulence-
related activities of the A. actinomycetemcomitans proteins and/or their paralogues in other
bacterial species.
(XLSX)
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S4 Table. COG definitions for all gene models of A. actinomycetemcomitans serotype e
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